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N-Acetylcysteine in the 
prevention of ototoxicity
M Tepel1
Prevention of ototoxicity after the administration of aminoglycoside 
antibiotics has been notably difficult, in particular in patients with 
chronic kidney disease. Feldman et al. report that oral administration 
of 600 mg N-acetylcysteine twice daily significantly ameliorates 
gentamicin-induced ototoxicity in hemodialysis patients. That 
approach may help to prevent aminoglycoside-induced hearing loss in 
these high-risk patients in daily practice.
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Severe sepsis (infection-induced organic 
dysfunction and hypoperfusion abnor-
malities) still causes high mortality.1 
Patients with chronic kidney disease 
on hemodialysis therapy oft en present 
with dialysis catheter-related bacteremia 
and sepsis. A combination of broad-
sp ec tr um ant ibiot ics  including 
aminoglycosides is frequently adminis-
tered as initial antimicrobial treatment. 
Nephrotoxicity and ototoxicity (in 
particular, hearing loss) are the major 
adverse events when aminoglycoside 
antibiotics are used. Commercial gen-
tamicin is a mixture of various conge-
ners and their enantiomers. Structural 
diff erences between them are limited 
to a methyl or hydrogen substitution 
in two residual groups on the purpuro-
samine residue. Bactericidal properties 
and cellular toxicity vary signifi cantly 
between diff erent congeners. However, 
pure bactericidal components that 
do not show ototoxicity are not com-
mercially available yet.2 Gentamicin-
induced ototoxicity may be related to 
increased oxidative stress in cochlear 
cells. Overexpression of the antioxi-
dant enzyme superoxide dismutase in 
inner-ear tissues of transgenic mice 
prevented kanamycin-induced hear-
ing loss, supporting the hypothesis that 
oxidative stress plays a signifi cant role in 
aminoglycoside-induced ototoxicity.3
In humans, prevention of ototoxicity 
aft er the administration of aminogly-
coside antibiotics has been notably dif-
fi cult. Th us the approach described by 
Feldman et al.4 (this issue), an approach 
that seems to be eff ective in ameliorat-
ing ototoxicity caused by gentamicin in 
patients with chronic kidney disease, 
will be greeted with great interest. Feld-
man et al.4 investigated the eff ect of the 
antioxidant N-acetylcysteine for protec-
tion of gentamicin-induced hearing loss 
in 40 hemodialysis patients with cath-
eter-related bacteremia in a prospec-
tive, randomized, controlled, open-label 
study. In the treatment group, 600 mg N-
acetylcysteine tablets were given twice 
daily. Gentamicin was administered for 
14 days. Two milligrams per kilogram 
of gentamicin over 30 minutes together 
with 2 grams of cephazolin aft er dialy-
sis was given. Six weeks aft er complet-
ing gentamicin therapy, 11 patients in 
the control group but only two patients 
in the N-acetylcysteine-treated group 
showed ototoxicity.4 Earlier animal 
studies are in accordance with such a 
protective eff ect of N-acetylcysteine on 
gentamicin-induced ototoxicity.5 Fur-
thermore, N-acetylcysteine also pre-
vented impulse noise-induced cochlear 
damage in animal studies.6 From these 
data it can be concluded that N-ace-
tylcysteine could be used as a simple, 
eff ective, and safe drug for prevention 
of aminoglycoside-induced ototoxicity 
in patients with chronic kidney disease 
on hemodialysis therapy.
As is customary, N-acetylcysteine was 
given orally in the study by Feldman et 
al.4 Although oral bioavailability of N-
acetylcysteine is quite low because it is 
quickly metabolized, N-acetylcysteine 
can be detected in plasma aft er a single 
600 mg dose in humans up to 1.5 hours 
aft er the drug is given.7 In healthy sub-
jects, N-acetylcysteine has a volume of 
distribution of 0.33 liters per kg and 
an elimination half-life of 2.27 hours.8 
N-Acetylcysteine is readily hydrolyzed 
to cysteine, which is a precursor of 
glutathione. Hence, increased plasma 
cysteine concentrations and increased 
plasma glutathione concentrations can 
be observed aft er oral administration of 
N-acetylcysteine in humans.7 Th e struc-
ture and some postulated mechanisms 
of N-acetylcysteine to reduce oxidative 
stress are shown in Figure 1 and Table 
1. Th e protective antioxidative eff ects 
aft er oral administration of N-acetyl-
cysteine may be related to its action as 
a free-radical scavenger, or as a reactive 
sulfhydryl compound that increases 
the reducing capacity of the cell. Glu-
tathione diminishes the harmful intra-
cellular eff ects of free oxygen radicals. 
Oxidative stress decreases reduced 
and increases oxidized glutathione. 
Thus, N-acetylcysteine can help to 
replenish depleted glutathione content 
when cells are exposed to elevated oxi-
dative stress.
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Figure 1 | Structure of N-acetylcysteine.
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N-Acetylcysteine has been used for 
treatment or prophylaxis of several dis-
tinct diseases that are associated with 
increased oxidative stress.9 Th is thiol-
containing antioxidant was used to treat 
a variety of pulmonary diseases and to 
ameliorate the toxic eff ects in a variety 
of experimentally or clinically induced 
ischemia–reperfusion syndromes of the 
heart, kidney, and liver.9 Furthermore, 
N-acetylcysteine causes vasodilatation 
in particular by enhancing the eff ects 
of nitric oxide, and it inhibits platelet 
aggregation. Because of its antioxida-
tive properties, N-acetylcysteine therapy 
has been used in unstable angina, acute 
myocardial infarction, heart failure, 
hypertension, and paracetamol poison-
ing, and in critically ill patients with 
sepsis, although with variable results. 
Finally, N-acetylcysteine is oft en used 
to prevent contrast-induced nephropa-
thy. However, at present there is limited 
evidence that acetylcysteine together 
with adequate hydration may be useful 
as standard prophylactic procedure in 
patients with a high risk for contrast-
induced nephropathy.10
Th e study by Feldman et al.4 describes 
a novel application of N-acetylcysteine, 
which is cheap and without major 
side effects. If their results are con-
fi rmed in additional studies, the oral 
administration of 600 mg N-acetyl-
cysteine twice daily may help to prevent 
aminoglycoside-induced hearing loss in 
daily practice.
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Table 1 | Postulated mechanisms of 
N-acetylcysteine to reduce oxidative 
stress
1.  Redox mechanism: Increase of cysteine, an 
antioxidant that can be oxidized to cystine
2.  Redox mechanism: Increase of glutathione 
(γ-glutamyl-cysteinyl-glycine; GSH), an 
antioxidant that can be oxidized to GSSG
3.  Formation of mixed disulfides with free 
sulfhydryl (SH) groups of cellular peptides
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A fat chance of renal injury
MP Koeners1 and JA Joles1
Williams et al. demonstrate in sheep that juvenile obesity per se 
leads to renal pathology but that prenatal undernutrition effectively 
abolishes any renal pathology associated with juvenile obesity. These 
peculiar findings are quite opposite to what has been documented in 
many epidemiological and animal studies. They provoke questions 
about how adverse developmental conditions can either support 
or compromise adaptation to excess nutrient intake and low motor 
activity later in life.
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William Shakespeare relates overweight 
and life expectancy in Henry IV, Part 
II. The king warns a “surfeit-swell’d” 
Falstaff : 
Make less thy body hence, and more thy 
grace; 
Leave gormandising; know the grave doth 
gape
For thee thrice wider than for other men.
Analogous recent literature suggests a 
relation between obesity and renal dis-
ease, and encourages weight loss, because 
this oft en leads to a reduction in pro-
teinuria.1,2 However, even though a lot 
of data suggest a linear relation between 
body mass index and proteinuria, the 
mechanisms involved remain elusive. 
Of course, most obese subjects do not 
develop renal disease. Hence, there must 
be other factors associated with obesity 
that lead to renal disease. Knowledge of 
these factors is important, because it will 
help us to counsel and treat overweight 
patients more effectively than simply 
recommending weight loss. Weight 
loss, although initially relatively easy, 
is hard to maintain. Even when main-
tained, weight loss might not always be 
the panacea that it is oft en considered 
to be.
Obese individuals oft en demonstrate 
hyperfiltration,3 and angiotensin-
converting enzyme inhibition is very 
eff ective in reducing their proteinuria.1 
Recently, drastic weight loss aft er bari-
atric surgery in morbidly obese patients 
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